Related Experiment Video
Updated: Mar 12, 2026

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
Published on: November 17, 2023
Significance of Gleason Score 7 With Tertiary Pattern 5 at Radical Prostatectomy
Walaa Borhan1, Jonathan I Epstein2
1Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD; Department of Pathology, Taibah University, Madinah, Saudi Arabia.
Objective:
To study the prognostic influence of tertiary pattern 5 (TP5) in radical prostatectomy specimens with a Gleason score of 7.
Materials And Methods:
A total of 4060 specimens with a Gleason score of 7 with and without TP5 seen between 2005 and 2015 were retrospectively reviewed. Cases were subdivided into 3 + 4 = 7, 3 + 4 = 7 with TP5, 4 + 3 = 7, and 4 + 3 = 7 with TP5. We compared prostate-specific antigen, clinical stage, pathologic stage, and surgical margin status between the groups. The impact of TP5 on biochemical recurrence was also assessed.
Results:
The median age was 68 years old with a median prostate-specific antigen level of 9.3 ng/mL. TP5 was present in 259 patients (6.4%) with a Gleason score 3 + 4 = 7 and in 361 patients (8.9%) with a Gleason score of 4 + 3 = 7. The mean follow-up without progression was 3 years. The presence of a tertiary pattern correlated with pathologic stage; the only exception was that there was no statistically significant difference between Gleason score 3 + 4 = 7 with TP5 and 4 + 3 = 7. Multivariate analysis showed that TP5 was independently associated with biochemical recurrence among patients with a Gleason score of 7 (P < .001). There was no difference between 3 + 4 = 7 with TP5 and 4 + 3 = 7 in terms of biochemical recurrence-free survival rate (P = .4).
Conclusion:
The impact of TP5 of Gleason score 7 in radical prostatectomy specimens is still significant using contemporary grading. Moreover, TP5 was independently associated with biochemical recurrence. However, 3 + 4 = 7 with TP5 behaves like 4 + 3 = 7 in terms of biochemical recurrence-free survival rate.

